Upcoming Pharma Projects in Gujarat: Key Plant Leads

Projects India tracks 463 upcoming drugs and pharmaceuticals projects in Gujarat, of which 407 are verified. Three new projects were added to our database in the last 90 days, matching the rate of the 90 days before that. Where project costs have been recorded, the combined figure stands at approximately Rs 13,473 crore — a pipeline that spans API manufacturing, bulk drug intermediates, formulation plants and specialty chemical units across Bharuch, Vadodara, Ahmedabad and several other clusters.

Gujarat pharma pipeline at a glance

Largest upcoming pharma projects in Gujarat

The table below lists the highest-value projects our records show across the state, covering bulk drugs, formulations, API intermediates and packaging-related manufacturing.

Several patterns stand out. Torrent Pharmaceuticals is the single most capital-intensive promoter in our database for this scope, with four projects totalling about Rs 1,306 crore — its Gandhinagar bulk drugs unit is already under construction with a December 2026 target. Bharuch dominates the list, with Dahej GIDC alone hosting multiple large-ticket investments from ACG Worldwide and Cadila Pharmaceuticals. The Rs 2,000 crore P&G health and wellness unit at Sanand remains on hold, making it the largest project in the pipeline that has not yet broken ground; when it moves, it will be significant for civil contractors and utility suppliers in the Ahmedabad belt.

Where the new pharma projects in Gujarat are concentrated

As the chart below shows, Bharuch accounts for the overwhelming majority of pharma and drugs projects tracked in Gujarat, followed by Vadodara and Ahmedabad.

Bharuch's dominance — 264 of all projects in our scope — reflects decades of GIDC estate development at Ankleshwar, Dahej, Panoli and Vagra. These estates offer common effluent treatment infrastructure, bonded warehousing and established contractor ecosystems, which is why promoters ranging from Schott Kaisha to SRF Limited continue to expand there. Vadodara, with 40 projects, is the next most active district; the Vaghodia and Gothda corridors near Vadodara house both formulation and intermediate manufacturing. Drugs and pharmaceuticals projects in Gujarat in the Ahmedabad district — 35 tracked — tend to concentrate at Sanand GIDC, where greenfield formulation investments by Puniska Healthcare sit alongside the stalled P&G project. Mehsana (26 projects) and Valsad (20) round out the top five, with Valsad's proximity to Vapi GIDC keeping it relevant for API and specialty chemical manufacturing.

For sales teams covering the state, the practical implication is that a Bharuch-first strategy reaches the largest share of active construction sites, but Ahmedabad and Vadodara offer the better access for formulation-stage work, where cleaner-room contractors, blister and packaging machinery suppliers and quality-lab consultants are in demand.

What stage are these projects at — and what does that mean for suppliers?

The stage distribution across all projects in this scope — including completed and cancelled ones — is shown in the chart below.

Of the projects our database tracks across all stages, 182 are currently under approvals — the single largest active group. This is the stage at which environmental clearances, consent-to-establish applications and layout approvals are being processed. Another 127 are under construction, representing the most immediate commercial opportunity: these projects are actively buying civil materials, process equipment, utilities and engineering services right now. A further 22 are in planning, meaning detailed engineering and vendor shortlisting may not have started but early conversations with promoters are worthwhile. The 57 projects on hold — including the large P&G and one Torrent unit — are worth monitoring because a change in promoter priorities or regulatory status can move them quickly into procurement mode. The 54 projects with approvals received but construction not yet started occupy a narrow window: budgets are largely set and EPC or turnkey contracts are typically close to being awarded at this stage.

New pharma projects added to our database recently

Three projects were added to the Projects India database in the 90 days to 16 October 2026. All three are in the Bharuch–Ahmedabad corridor and reflect the continued activity in Ankleshwar and the city of Ahmedabad.

• Bulk Drugs Intermediates Mfg Unit at Ankleshwar (Expansion) — Valeshvar Biotech Private Limited, Ankleshwar, Bharuch. Stage: Under Approvals. Cost not yet recorded.
• Bulk Drugs Mfg Unit at Ankleshwar (New) — VB Genetics Private Limited, Ankleshwar, Bharuch. Cost: Rs 7 crore. Stage: Construction Started.
• API & Intermediates Mfg Project at Ahmedabad — Dwirayu Pharma Private Limited, Ahmedabad. Cost: Rs 7.5 crore. Stage: Under Approvals.

All three are smaller-scale units, consistent with the MSME character of much of the Ankleshwar estate. The Valeshvar Biotech expansion is worth watching because its cost has not yet been disclosed — that figure typically appears once the environmental or consent application is filed. Suppliers of reactor vessels, distillation columns and effluent treatment systems who cover the Ankleshwar cluster should flag these early, since procurement decisions on smaller units are made quickly and without long tender cycles. For context on how MSME-scale industrial plant leads behave across India, our MSME project report on industrial plant leads offers a useful reference.

Most active promoters in Gujarat pharma

As the chart below shows, Torrent Pharmaceuticals leads by combined recorded cost, while several mid-size promoters — Pranami Drugs, Mahrshee Laboratories, Corona Remedies — each have three projects in our records, suggesting a programme of staged capacity additions rather than single large investments.

Glenmark Life Sciences Limited has two projects worth about Rs 387 crore and Glenmark Pharmaceuticals Limited has two projects worth about Rs 304 crore in recorded cost across both entities. ACG Worldwide's Rs 400 crore capsule unit at Dahej is its largest single Gujarat commitment in our database. Alembic Pharmaceuticals, with two projects totalling about Rs 326 crore including the Vaghodia tablets and capsules plant, is a consistent builder in the Vadodara corridor. Promoters such as Dishman Carbogen Amcis (two projects, about Rs 162 crore) and Icon Pharma Chem (two projects, about Rs 146 crore) represent mid-tier contract manufacturing and API businesses that often purchase from smaller, specialised equipment vendors rather than large EPC firms.

What this means for suppliers and contractors

Each project stage in this pipeline calls for a different type of vendor conversation.

• Construction Started (127 projects): Civil contractors, structural steel fabricators, process piping firms, HVAC and clean-room specialists, electrical and instrumentation contractors, and capital equipment suppliers for reactors, dryers, centrifuges, granulators and tablet presses should be most active here. Procurement is live and delivery timelines are firm.
• Approvals Received (54 projects): Detailed engineering is either in progress or about to begin. EPC contractors, project management consultants and early-stage equipment vendors should be qualifying these promoters now. Budget discussions are possible.
• Under Approvals (182 projects): The largest group, and the best place to build relationships before competition intensifies. Environmental consultants, consent-to-establish advisors, land and utility planners, and pre-project engineering firms are relevant here.
• Planning (22 projects): Feasibility consultants, technology licensors, site selection advisors and financial modellers are the right entry point at this stage.
• Hold (57 projects): Monitor, do not pursue actively. A project moving off hold — especially the large P&G unit or the second Torrent bulk drugs plant — represents a sudden, large procurement opportunity for suppliers already known to the promoter.

For contractors already working in Gujarat's industrial clusters, the industrial projects pipeline in Gujarat sits alongside the pharma vertical and often shares the same GIDC estate infrastructure, site contractors and material supply chains. Cross-sector visibility helps in resource planning. Teams looking for live tender opportunities can also explore government and private tenders in the pharma and chemicals space.

How to track upcoming pharma projects in Gujarat

The 463 projects described here are drawn from the Projects India projects intelligence database, which covers upcoming private and government projects, tenders and awarded contracts across India — 84,593 projects nationally as of the date of this report. Each pharma project record includes the promoter, location, project cost where available, current stage, expected completion date where filed, and verification status.

For teams selling equipment, engineering services or raw materials into Gujarat's pharma clusters, early identification — particularly at the Under Approvals and Planning stages — is where most of the commercial advantage lies. The full list of drugs and pharmaceuticals projects in Gujarat on Projects India can be filtered by city, stage, cost range and promoter. A free sample project report is available for teams evaluating the database before committing to a subscription. Suppliers and contractors looking to identify the right counterparts for specific projects can also use VendorConnect, our contractor and supplier directory, to map the ecosystem around each cluster.